Login to Your Account



Mesoblast IP agreement shores up Tigenix’s rights in adult stem cell market

By Tamra Sami
Staff Writer

Monday, December 18, 2017

PERTH, Australia – Belgium’s Tigenix NV licensed intellectual property from Australian stem cell company Mesoblast Ltd. the same day it announced approval of the EU’s first allogeneic stem cell therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription